Skip to main content

TransMedics Group Inc

For the period ended Dec 31, 2023. Filed Feb 27, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Feb 27, 2024

TMDX$93.79+6.3%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Item 9B. Other Information

During our fiscal quarter ended December 31, 2023, one of our directors entered into a contract, instruction or written plan for the purchase or sale of our securities that is intended to satisfy the conditions specified in Rule 10b5-1(c) under the Exchange Act for an affirmative defense against liability for trading in securities on the basis of material nonpublic information. We refer to these contracts, instructions, and written plans as “Rule 10b5-1 trading plans” and each one as a “Rule 10b5-1 trading plan.”

We describe the material terms of this Rule 10b5-1 trading plan in the table below.

Rule 10b5-1 Trading Plans

Maximum
Number
of Securities to
Scheduled · be Purchased or
Action · Commencement · Termination · Sold Pursuant to · Covers
and Dateof Tradingof TradingSecuritythe Rule 10b5-1Purchase
Director/Officerof ActionPeriodPeriod (1)CoveredTrading Plan (2)Or Sale
James Tobin, Chairman of the Board of DirectorsAdoption21-Nov-2320-Feb-2430-Dec-24Common Stock40,445Sale

(1)

The plan is subject to earlier termination under certain circumstances specified in the plan, including upon the sale or purchase (as applicable) of all shares subject to the plan and upon either party to a plan giving notice of termination within the time prescribed under the plan.

(2)

Subject to adjustments for stock splits, stock combinations, stock dividends and other similar changes to our common stock.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.